Meld Valuation / Venture NAV Tracker
FundsCompaniesMethodology
meldvaluation.com ↗

Venture NAV Tracker / Fund

Horizon Technology Finance Corporation (HRZN)

An externally managed BDC providing secured venture loans to technology and life science companies; its merger with Monroe Capital Corporation closed 2026-04-14, after the Q1 balance-sheet date.

Fund website ↗
Structureventure debt BDC
ExchangeNASDAQ
NAV / share$6.98Mar 31, 2026 · source ↗
Market price$4.66Jul 17, 2026 · source ↗
Premium / discount-33.2%Derived from latest NAV and price
Net assets$333.9MMar 31, 2026 · source ↗

Latest observation

NAV vs. market price

Reported dates shown below.

NAV / share$6.98Mar 31, 2026 · source ↗
Market price$4.66Jul 17, 2026 · source ↗

Fund facts

Manager
Horizon Technology Finance Management LLC
NAV frequency
quarterly
Primary filing
10-Q
Expense ratio
—

Schedule of investments

Debt investments

Mar 31, 2026 reporting period

CompanySecurity typePrincipalCostFair valueFV / principalRateMaturityNon-accrual
Pelthos TherapeuticsBiotechnologysenior secured loan$30MMar 31, 2026 · source ↗—Mar 31, 2026 · source ↗$29.4MMar 31, 2026 · source ↗97.9%Mar 31, 2026 · source ↗P+3.75% (10.50% floor, 5.00% ETP)Mar 31, 2026 · source ↗Jan 31, 2031Mar 31, 2026 · source ↗NoMar 31, 2026 · source ↗
Castle Creek BiosciencesBiotechnologysenior secured loan$25.5MMar 31, 2026 · source ↗—Mar 31, 2026 · source ↗$25.4MMar 31, 2026 · source ↗99.5%Mar 31, 2026 · source ↗P+4.25% (12.00% floor, 4.00% ETP)Mar 31, 2026 · source ↗Mar 1, 2028Mar 31, 2026 · source ↗NoMar 31, 2026 · source ↗
Long Grove PharmaceuticalsPharmaceuticalssenior secured loan$10.4MMar 31, 2026 · source ↗—Mar 31, 2026 · source ↗$10.2MMar 31, 2026 · source ↗98.0%Mar 31, 2026 · source ↗1M SOFR+4.00% (6.00% floor)Mar 31, 2026 · source ↗Feb 27, 2031Mar 31, 2026 · source ↗NoMar 31, 2026 · source ↗

Schedule of investments

Warrant & equity positions

Mar 31, 2026 reporting period

CompanyFair value% of NAVSecurityImplied price / shareMethodology / source

Position history

Reported fair-value marks

Each bar is a disclosed position-quarter.

$25.4MCastle Creek BiosciencesMar 31, 2026 · source ↗$29.4MPelthos TherapeuticsMar 31, 2026 · source ↗$10.2MLong Grove PharmaceuticalsMar 31, 2026 · source ↗
Figures are compiled from public filings.Read methodologyMELD Valuation